

This is the peer reviewed version of the following article:

Characterization of copy number variants in hereditary cancer patients through NGS shows a distinctive PALB2 contribution to the diagnostic yield / Bonamici, L., Artuso, L., Marino, M., Toss, A., Sidoti, D., Barbieri, E., Venturelli, M., Marchi, I., Pescucci, C., Manfredini, R., Papi, L., Dominici, M., Cortesi, L., Tenedini, E., Tagliafico, E.. - In: HUMAN MUTATION. - ISSN 1059-7794. - 2026:1(2026), pp. 1-3. [10.1155/humu/6601291]

*Terms of use:*

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

29/10/2026 20:19

**Characterization of copy number variants in hereditary cancer patients through NGS shows a distinctive PALB2 contribution to the diagnostic yield.**

Lia Bonamici<sup>1,2</sup>, Lucia Artuso<sup>2</sup>, Marco Marino<sup>2</sup>, Angela Toss<sup>1,3</sup>, Diletta Sidoti<sup>4</sup>, Elena Barbieri<sup>3</sup>, Marta Venturelli<sup>1,3</sup>, Isabella Marchi<sup>3</sup>, Chiara Pescucci<sup>4</sup>, Rossella Manfredini<sup>5,6</sup>, Laura Papi<sup>4</sup>, Massimo Dominici<sup>1,3</sup>, Laura Cortesi<sup>1,7</sup>, Elena Tenedini<sup>1,2,\*§</sup> and Enrico Tagliafico<sup>1,2,\*</sup>.

1. Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.

2. Diagnostic Hematology and Clinical Genomics Unit, Department of Laboratory Medicine and Pathology, Modena University Hospital, Modena, Italy

3. Oncology Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy

4. Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.

5. Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.

6. Interdepartmental Centre for Stem Cells and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy

7. UOC Oncologia, Azienda USL-IRCCS Reggio Emilia, Reggio Emilia, Italy

\* These authors equally contributed to the work

§ Correspondence to: Elena Tenedini, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Via del Pozzo 71, 41124 Modena, Italy  
e-mail: elena.tenedini@unimore.it  
phone number +390594222956

**Running title:**

copy number variants with a multigene NGS panel in hereditary cancer patients

## ABSTRACT

The extensive use of Next Generation Sequencing (NGS) multi-gene panels and advanced analysis algorithms have led to the identification of numerous genetic variants associated with breast, ovarian, and pancreatic cancer. Copy Number Variations (CNVs), defined as deletions and duplications of specific DNA regions, account for up to 10% of pathogenic variants and can affect any of the cancer-predisposing genes. Despite this, CNVs contribution beyond BRCA1 and BRCA2, remains underexplored.

This observational study analyzed data from 2949 patients, primarily affected by breast or ovarian cancer, who underwent NGS testing with a 22-gene hereditary cancer panel between 2018 and 2023, with a focus on CNVs results.

In line with comparison studies a total diagnostic yield of 14.8% was observed with pathogenic variants in BRCA1, BRCA2, CHEK2, ATM, and PALB2 accounting for most of positive findings.

In contrast, CNVs were found in 1.4% of patients, displaying a peculiar distribution pattern.

PALB2 exhibited the highest frequency of pathogenic CNVs (66.7%), representing 62.2% of all PALB2 pathogenic variants. Notably, 24 out of 28 PALB2 CNV carriers shared the deletion of Exon 11. Further investigations revealed identical breakpoints and common geographical origins, and moreover, the same haplotype for some of the families suggests a relatively recent founder effect.

Simultaneous sequence and copy number analyses resulted in likely higher positive predictive value of the test and, more interestingly, disclosed an unforeseen single contribution of CNVs in PALB2 gene, confirming geography as a key factor in shaping human genetic variations.

## INTRODUCTION

The genetic risk assessment for breast, ovarian, and pancreatic cancer, was primarily focused on testing *BRCA1* and *BRCA2* genes<sup>1,2</sup>. Next-generation sequencing (NGS) has represented a paradigm shift for genetic testing, enabling high-throughput analysis of multiple genes, reducing time and costs<sup>3</sup>. This has renewed researcher's interest and unveiled an ever-growing list of genes associated to different levels of cancer risk<sup>4-8</sup>. The latest clinical recommendations, as outlined in the National Comprehensive Cancer Network Clinical Practice Guideline in Oncology (NCCN Guidelines®)<sup>9</sup>, suggest offering multigene test panels including high and moderate-risk genes associated with hereditary neoplasms, to patients suggestive of genetic predisposition to cancer<sup>10,11</sup>. Despite these advancements, a considerable portion of DNA alterations that cause tumor predisposition remains unexplored<sup>12,13</sup>. Among these, Copy Number Variations (CNVs) that represent a challenging class of structural DNA variants, such as deletions or amplifications, remains underreported<sup>6,14,15</sup>.

For many years, Multiplex Ligation-dependent Probe Amplification (MLPA), and Chromosomal Microarray Analysis, have been broadly used in clinics for CNVs detection<sup>16</sup>. Although these technologies are accurate, they considerably impact turnaround times and costs of the diagnostic routine<sup>17-20</sup>. More recently, algorithms with high-grade reliability and accuracy were developed to detect CNVs from NGS data<sup>20,21</sup>. NGS has therefore become a first-approach single test that streamlines the detection of genomic alterations across many genes, including both sequence variants (Single Nucleotide Variants or Indels), and CNVs<sup>12,16,22,23</sup>. This advance has expanded the diagnostic application of NGS and collection of data about CNVs<sup>6,22</sup>.

Nevertheless, MLPA remains essential as a confirmatory method<sup>12</sup>, particularly for high complexity regions, which are still challenging for short-reads alignment algorithms.

Previous studies in hereditary cancer settings have established that CNVs account for around 7-10% of all pathogenic variants (PVs) and are not limited to *BRCA1* and *BRCA2* but also occur in

other high or moderate risk genes, like *PALB2*, *ATM*, *CHEK2* and *RAD51C*<sup>6,12,19,24,25</sup>. These results confirm the need to offer a broader, robust and accurate CNVs testing, since comprehensive analysis can optimize medical decisions for patients and their families<sup>22</sup>. This monocentric study aimed to examine prevalence and characteristics of genetic alterations, with a particular focus on CNVs results, in 2949 consecutive patients who underwent NGS testing with a multigene panel for hereditary cancer during a six-years period, from 2018 to 2023.

## **MATERIAL AND METHODS**

### **Study population**

Data were collected from consecutive patients who underwent genetic testing for Hereditary Cancer risk assessment from January 2018 to December 2023 at single testing center (2949 total), with a service area including patients living in two provinces of Modena and Reggio Emilia, Italy. Personal or familial inclusion criteria were evaluated during pre-test genetic counseling, in accordance with the current guidelines of the Italian public healthcare system, as described before<sup>26,27</sup>. Medical history and demographic elements were acquired from clinical indications prompting the test. This retrospective observational monocentric study was conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonization and the Declaration of Helsinki. The study was approved by the local Ethics Committee (number 32/2024/OSS\*/AOUMO SIRER ID 7122).

### **Sample collection and DNA isolation**

Genomic DNA isolation from peripheral blood (PB) samples was performed with either the DNA Midi Kit via the QIASymphony platform (QIAGEN, Hilden, Germany) or the Maxwell 16 LEV Blood DNA Purification Kit (Promega, Madison, WI, USA), according to the manufacturers' instructions. Fluorometric quantification of nucleic acids was carried out with a Qubit dsDNA High Sensitivity kit (Thermo Scientific, Waltham, MA, USA).

## NGS Panel

The entire study population was tested using the CE-IVD NGS-based multigene panel Hereditary Cancer Solution (HCS) v1.1, by SOPHiA GENETICS™ (Sophia Genetics, Lausanne, Switzerland). The hybridization capture-based library preparation was carried out as previously described<sup>28</sup>. The design allows for the enrichment of coding and splicing regions of genes associated with hereditary cancer (*APC*, *ATM*, *BARD1*, *BRCA1*, *BRCA2*, *BRIP1*, *CDH1*, *CHEK2*, *EPCAM*, *FAM175A*, *MLH1*, *MRE11A*, *MSH2*, *MSH6*, *MUTYH*, *NBN*, *PALB2*, *PIK3CA*, *PMS2*, *PTEN*, *RAD50*, *RAD51C*, *RAD51D*, *STK11*, *TP53*, *XRCC2*) along with the pseudogene *PMS2CL*. The samples were sequenced in a 24 samples per run format, with a MiSeq Reagent Kit v3 (2X 300bp paired-end reads), on the Illumina® MiSeq® DX platform (Illumina®, San Diego, CS, USA), following the Illumina® and SOPHiA GENETICS™ indications. A minimum coverage of 200X was achieved in all the target regions.

## Data analysis and interpretation of genetic variants

The sequencing data were processed simultaneously with two separate algorithms, using the CE-IVD SOPHiA Data Driven Medicine™ (DDM™): platform for detecting both sequence variants (Single Nucleotide Variants and Indels), and Copy Number Variations (CNVs). CNVs were detected using a proprietary algorithm based on coverage calculation of targeted regions, after applying double normalization within samples of the same run (both sample-specific and region specific), to avoid bias. In this study, we refer to CNVs as duplications or deletions affecting one or more exons of a gene.

Data analysis and interpretation were limited to a virtual panel of 22 actionable genes (*APC*, *ATM*, *BARD1*, *BRCA1*, *BRCA2*, *BRIP1*, *CDH1*, *CHEK2*, *EPCAM*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NBN*, *PALB2*, *PMS2*, *PTEN*, *RAD50*, *RAD51C*, *RAD51D*, *STK11*, *TP53*), according to the patients' informed consent. For the variant annotation process, the output from SOPHiA DDM™ was enriched with data from the literature, public databases (ClinVar<sup>29</sup> and LOVD<sup>30</sup>) and

additional open-sources bioinformatics tools such as Varsome<sup>31</sup>, Annovar<sup>32</sup>, Franklin by Geenox (<https://franklin.genoox.com>) and Variant Effect Predictor<sup>33</sup> (VEP).

Sequence Variants were reported using the standard international HGVS (Human Genome Variation Society) nomenclature and classified according to the American College of Medical Genetics and Genomics (ACMG)<sup>34</sup> in five classes (C1-C5): pathogenic (P), likely pathogenic (LP), variant of uncertain significance (VUS), likely benign (LB), and benign (B). CNVs were evaluated according to ACMG and ClinGen standards<sup>35</sup> with the CNV classification calculator (<http://cnvcalc.clinicalgenome.org/cnvcalc/>).

### **Variants confirmation**

The sequence variants classified as pathogenic or likely pathogenic (LP/P) were confirmed by Sanger sequencing as already described<sup>26</sup>. Sequencing data were analyzed with SeqScapeSoftware3.0 (Thermo Fisher Scientific, Waltham, MA, USA). For all the CNVs, orthogonal confirmatory tests were performed with the Multiplex Ligation-dependent Probe Amplification (MLPA) (MRC-Holland, Amsterdam, The Netherlands) technology and according with the manufacturer's protocols. Results were analyzed with the Coffalyser.Net software (MRC-Holland) updated to the latest available version at the time of testing.

### ***PALB2* Breakpoints characterization**

To characterize the genomic breakpoint in *PALB2* exon 11 deletion heterozygotes, long-range PCR was performed using Platinum Taq DNA polymerase High Fidelity (Thermo Fisher Scientific) to generate a 13975bp amplicon, spanning from the start of exon 10 to the end of exon 12 [NC\_000016.9:g.23619120\_23633094 (NC\_000016.10:g.23607800\_23621774 on GRCh38]. The following commercially available M13-tailed primers were used:

Hs00439505\_CE, Hs00733432\_CE (Thermo Fisher Scientific). Each 50µL reaction contained 300ng of template DNA. The amplification conditions were as follows: 94°C for 30 seconds, followed by 35 cycles at 94 °C for 15 seconds, 64°C for 30 seconds and 68 °C for 15 minutes.

The PCR products were analyzed using the Agilent 4200 TapeStation system (Agilent

Technologies, Santa Clara, CA, USA) with Genomic DNA ScreenTape assay, to confirm the amplification products.

PCR products were subjected to Sanger sequencing with multiple custom primers designed with the Invitrogen OligoPerfect Designer (Thermo Fisher Scientific) to cover the flanking regions of AluSz, AluSp, AluYa5, AluSx, AluY elements in introns 10 and 11. RepeatMasker software (<https://www.repeatmasker.org/cgi-bin/WEBRepeatMasker>) was used to identify genomic positions of repeated Alu elements within the *PALB2* sequence. The genomic breakpoint was identified using the following reverse primer:

ALU\_SZ\_R4: 5'-CATCAGTGTTCAGAGGAACC-3'. Sequencing reaction was performed using BigDye™ Terminator v3.1. Capillary electrophoresis was performed on the 3500xL Dx Genetic Analyzer (Thermo Fisher Scientific). The collected data were analyzed and verified with SeqScape software v3.0 (Thermo Fisher Scientific).

Assessment of the *PALB2* exon 11 tandem duplication was performed using PCR primers and experimental conditions as described by Bouras et al<sup>36</sup>.

#### **Microsatellite Analysis and Haplotyping**

Microsatellite markers flanking the *PALB2* locus on chromosome 16 were genotyped using six polymorphic short tandem repeat (STR) loci: D16S3075, D16S3103, D16S3046, D16S3068, D16S3136, and D16S415. These markers were obtained from the ABI PRISM® Linkage Mapping Set v2.5 (Applied Biosystems, Thermo Fisher Scientific). PCR amplification was performed according to the manufacturer's protocol, and the resulting amplicons were resolved by capillary electrophoresis on a SeqStudio™ Genetic Analyzer (Applied Biosystems, Thermo Fisher Scientific). Fragment analysis was conducted using GeneMapper® Software v6.0 (Applied Biosystems, Thermo Fisher Scientific), enabling precise allele sizing and genotyping. A total of 35 individuals from eleven informative families, both carriers and non-carriers of the *PALB2* exon 11 deletion, were genotyped. Haplotype reconstruction was performed manually

based on the microsatellite genotyping data, assuming the minimum number of recombination events required to explain the observed allele segregation.

## **Statistical Analysis**

Categorical variables were reported as absolute and percentage frequencies. Data were analyzed using Fisher's exact test to identify associations between categorical variables. All analysis were performed with R software version 4.4.0 (R Core Team 2024, <https://www.R-project.org>). Adjusted P-values <0.05 were considered statistically significant.

## **RESULTS**

### **Patient details and yield of reported variants**

We collected genetic test results and clinical data from a consecutive series of 2949 patients, predominantly of European ancestry, referred to the laboratory for evaluation by a NGS panel for hereditary cancer, between January 2018 and December 2023. Written informed consent was obtained from all patients to undergo NGS testing for 22 genes (*APC*, *ATM*, *BARD1*, *BRCA1*, *BRCA2*, *BRIP1*, *CDH1*, *CHEK2*, *EPCAM*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NBN*, *PALB2*, *PMS2*, *PTEN*, *RAD50*, *RAD51C*, *RAD51D*, *STK11*, *TP53*). Personal and family histories of cancer were provided by the referring clinicians and the most part, 2887/2949 (97.9%), had a personal tumor history (see Supplementary Table 1). Among the affected, 1503/2887 individuals (52.1%) received a breast cancer diagnosis and 200 (6.9%) had breast cancer before the age of 40 and were defined as Early Onset Breast Cancer (EOBC). 515/2887 cases (17.8%) were Triple-Negative Breast Cancers (TNBC), 62 patients (2.1%) were Male Breast Cancer (MBC) and 4 (0.1%) had MBC and Prostate Cancer. 144 patients (5.0%) were diagnosed with ovarian cancer, while a minor part had BC and OC (1.4%) or either BC or OC and another neoplasia, 3.1% and 0.5% respectively. Pancreatic cancer cases accounted for 226 (7.8%) patients, and 8 individuals (0.3%) had both pancreatic and prostatic cancers. The subgroup of other cancers encompassed patients with personal history of melanoma, sarcoma,

renal carcinoma, gastric, colorectal, uterine or thyroid cancer. A positive family history of neoplasia was reported in 2428/2949 patients (82.3%) (Supplementary Table 1). Sequence variants (SNVs and Indels), and CNVs classified as VUS, Likely Pathogenic, and Pathogenic were included in the patients' genetic reports. More than half of the tested individuals, 57.0% (1681/2949), were found to carry reportable variants. Of those, 1246 (42.2%) had VUS but 435 individuals were detected with one or more LP or P genetic variants, accounting for a whole positive diagnostic yield equal to 14.8% (Supplementary Table 1). Not surprisingly, sequence variants were the vast majority, with 395/435 individuals (90.8%), and CNVs the minor part, with 42/435 individuals (9.7%). Only two patients with both SNVs and CNVs.

#### **Comparison of results with literature data**

A comparison between results obtained in our study population and other patients' cohorts was performed searching the literature for papers with similar testing admission criteria, prevalence of affected subjects and sequenced genes.

In most cases patients of the selected six cohorts, had a European geographic ancestry and a personal history of breast cancer, as shown in Supplementary Table 2. They were all tested for variants with a NGS approach, looking for sequence variants and large rearrangements with commercial or custom panels focused on tumor suppressor genes involved in DNA repair mechanisms. Indeed, a common core of 9 genes (*ATM*, *BRCA1*, *BRCA2*, *PTEN*, *TP53*, *CDH1*, *PALB2*, *STK11*, *CHEK2*) is recurrent in the employed multigene panels and more than 80% of all the patients were tested for these genes.

The whole positive yield spanned from 9.0 to 22.1%, setting our result (14.8%) in the middle of the range (Supplementary Table 2). Otherwise, we classified variants as with undetermined clinical significance (VUS, ACMG class 3) in 1246/2949 individuals (42.2%), which represent the highest yield among the studies. As expected, *BRCA1* and *BRCA2* were the most frequently mutated genes across the cohorts, along with *CHEK2*, *ATM*, and *PALB2*. According to

published results, variants in these five genes describe the majority of positive findings, representing in our cohort 299/435 (68.7%) of positive patients (Supplementary Figure 1).

### **Comparison of copy number variations results with published available data**

Fifty-three individuals carried variations of copy number in at least one of the tested genes, accounting for 1.8% (53/2949) of the total analyzed cases. Deletions together with two in-tandem duplications, were classified as likely pathogenic or pathogenic (LP/P), making a total of 42/435 (9.7%) positive patients (Table 1). The full list of CNVs is reported in the Supplementary Table 3.

The prevalence of LP/P CNVs in all the analyzed individuals (1.4%), as well as the prevalence in the positive patients (9.7%), aligns with the highest rates reported in the comparison studies (Table 1). However, the distribution of this kind of variations among the genes exhibits a distinctive pattern, as shown in Figure 1. While structural variants in the other cohorts, primarily involve *BRCA1*, we identified a significantly higher number of pathogenic CNVs in the *PALB2* gene, accounting for 66.7% (28/42) of the total LP/P CNVs. Indeed, 62.2% (28/45) of total *PALB2* positive patients carry large deletions or duplications. This is in contrast with other cohorts, where CNVs in *PALB2* do not exceed 7% of all the copy number variations and typically represent only a small fraction (0-9.6%) of all deleterious variants found in this gene (see Table 1).

### ***PALB2* variants**

In the entire cohort, 45 patients tested positive for pathogenic CNVs and SNVs in *PALB2*, accounting for 1.5% of all tested individuals. Moreover, 94 patients (3.1%) harbor a variant with yet undetermined significance (ACMG class 3).

SNVs along with the Indels (111 in total, ACMG class 3-5), are distributed across the entire length of the coding sequence, as illustrated in Figure 2. A small fraction (17/111) was classified as pathogenic and impacts the portions of the gene coding for domains involved in interactions with DNA and other proteins (shown in Figure 2 and details summarized in Supplementary

Table 4). Of these variants, 9/17 occur in the largest exons 4 and 5, and most of them (14/17) disrupt the reading frame, resulting in a non-functional protein.

On the contrary, CNVs do not span the entire coding sequence, but cluster (26 out of 28 patients) from exon 8 up to 13 that code for the WD40 domain of the protein. Even more interestingly, 24/2949 patients harbor the deletion of Exon 11 (Figure 2 and Supplementary Table 4). They are consecutive index cases belonging to different families and none of them had other concomitant clinically relevant variants, except one with a likely pathogenic SNV in *BRIP1* (data not shown).

Nineteen out of 24 patients were diagnosed with breast cancer, including seven with a triple negative phenotype and 3 with bilateral breast cancer, while 5 were diagnosed with pancreatic cancer, as listed in Supplementary Table 4. All the patients reported a positive family history of cancer.

A total of 63 family members were tested for the deletion, and 23 were confirmed as positive heterozygotes (data not shown).

Breakpoints were characterized in carriers by amplification of genomic region encompassing *PALB2* region from Exon 10 to Exon 12. Sanger sequencing revealed that all the patients share the same 8204 base-pairs (bp) deletion [NC\_000016.9:g.23622528\_23630732del, (NC\_000016.10:g.23611207\_23619411del on GRCh38)], with the 5' and 3' breakpoints located within AluSx on intron 10 and AluSx1 in intron 11, respectively. Further comparison with already reported CNVs, as shown in Figure 3, allowed us to refine the characterization of the cases previously described by Sidoti et al.<sup>38</sup> revealing identical breakpoints with those identified in the current study. Details and coordinates are provided in Supplementary Table 5.

The geographic distribution of patients' birthplaces was analyzed to investigate whether a founder effect might account for the high prevalence of this Exon 11 deletion. Notably, all the 24 patients belong to local families and were born in a specific area within the provinces of Modena

and Reggio Emilia: a narrow flat region that borders to the south by the Apennine Mountain range and to the north by the Po River (Supplementary Figure 2). No patients from the hilly or mountainous area of the Apennines, nor any born extra region or extra nation were found to be carriers of the Exon 11 deletion.

To further investigate the possibility of a common ancestor, haplotype analysis was performed. Eleven families out of the 24 carrying the deletion of *PALB2* exon 11 were investigated using polymorphic markers spanning the *PALB2* locus. Genotyping was conducted on probands and additional family members, with two to four individuals analyzed per family. One main haplotype was associated with the deletion and shared by six families (F3, F7, F9, F10, F16, F19), as shown in Figure 4. One family (F2) shared the distal portion of the haplotype, most likely due to a recombination event between *PALB2* and D16S3046, whereas the remaining two families exhibited private haplotypes (Figure 4). Importantly, the haplotypes associated with the deletion were absent in non-carrier relatives.

## DISCUSSION

Copy number variations (CNVs) are known contributors to hereditary cancer, accounting for a small but significant fraction of patients<sup>6,12</sup>. In this study, we described the results of a single-center cohort of patients tested for 22 genes, analyzed simultaneously for sequence and CNVs. The variability observed when comparing our cohort to others can be reasonably explained in selection criteria for genetic testing, the proportion of affected versus unaffected individuals, the distribution of cancer types, and the total number of tested patients. Despite these differences, the overall diagnostic yield of 14.8% observed in our study remains consistent with the reported range of 10-20% for germline variants associated with hereditary cancer<sup>6,7,39,40</sup>. Likewise, clinically relevant sequence variants were identified in all genes, except for *STK11*, and the most frequently mutated genes (*BRCA2*, *BRCA1*, *CHEK2*, *ATM* and *PALB2*) align with findings

from comparison studies, account for 68.7% of total positive patients<sup>4,6,13,19,24,25</sup>. Only few patients are reported with deleterious sequence variants in one of the remaining tested genes, suggesting that each gene beyond this core set, has a minimal impact on the total diagnostic yield.

As far as large rearrangements are concerned, the observed overall percentage of pathogenic copy number variations (9.7% of positive patients), is consistent with the previously described 7-10% rate among positive individuals<sup>6,12,19</sup>, but its distribution among the tested genes differs significantly. Deleterious CNVs were found in just few genes (*PALB2*, *BRCA1*, *BRIP1*, *ATM*, *PMS2*, *CHEK2*, *BARD1*, *BRCA2*, *CDH1*, *MLH1* and *PTEN*) and surprisingly more than half of deletions and duplications occurred in one single gene, the partner and localizer of *BRCA2*, *PALB2*. It encodes a protein that promotes stability and localization of Brca2 and stimulates Rad51 function<sup>41,42</sup>, playing an essential role in the homologous recombination repairing of DNA. In recent years, *PALB2* has emerged as one of the most important cancers predisposing genes<sup>43</sup>, conferring an increased risk of breast<sup>8,44–47</sup>, pancreatic<sup>48</sup>, gastric and ovarian cancer<sup>49</sup>.

The growing number of clinical trials encompassing germline *PALB2* mutations as inclusion criteria<sup>50</sup>, highlights the increasing interest for this gene to improve patient clinical management. In contrast to studies describing *PALB2* deletions and duplications to be generally uncommon, reaching a maximum percentage of 7% of identified LP-P CNVs<sup>4,6,12,17,19,20,24,25</sup>, our data show a percentage of 66.7%, which is much higher. The very high number of single-copy losses or gains identified in our cohort, affect the WD40 domain (26/28 patients), known to be crucial for interactions of Palb2 with DNA damage repair proteins<sup>44</sup> and confirming the previous observation of Yang and colleagues that observed that exon deletions or duplications of this gene clustered in that domain<sup>47</sup>. Moving forward, 24/28 patients (85.7%) share the same single-copy deletion of Exon 11. No data are actually present in frequency databases and only very few cancer patients have been reported with this deletion<sup>4,37,38,48,51,52</sup>. All the individuals with exon 11 deletion were affected at the time of testing: 19/24 (79.2%) with a personal diagnosis of

breast cancer, including 7/19 (36.8%) TNBC cases, and 5/24 (20.8%) with pancreatic cancer. Interestingly, a high number of pancreatic cancers were observed in this subgroup compared to all the individual affected with no exon 11 deletion. Despite the modest size of our population a statistically relevant association ( $p=0.04$ ) was found, supporting the hypothesis that this variant may positively correlate with a higher risk of developing pancreatic cancer.

Schrader and colleagues<sup>37</sup> tested positive for Exon 11 deletion, an Ashkenazi Jewish female with a history of ovarian and breast cancer, but after the analysis of more than a thousand probands with familial breast, ovarian, or pancreatic cancer, they proved that this deletion variant does not appear to be a founder mutation in Ashkenazim<sup>37</sup>. No other information about a common geographical or ethnic origin can be inferred from the very few carriers described in the rest of the literature<sup>4,48,51,52</sup>, except for the cases recently reported by Sidoti and colleagues<sup>38</sup> in the near Tuscany region of Northern Italy. In this cohort, the deleted positive heterozygotes are apparently unrelated index cases; they share a common area of birth, namely provinces of Modena and Reggio Emilia, a plain territory divided from Tuscany by the Appennino mountains. They harbor a common 8204 base pairs deletion with identical breakpoints. Deletion size and boundaries are completely distinct from the single case described by Schrader<sup>37</sup>, while they turned to be identical to the deletion described by Sidoti<sup>38</sup>. The deletion breakpoints occur within Alu repeat elements AluSx/AluSx1, confirming that Alu mediated non-allelic homologous recombination is the most likely causative molecular mechanism<sup>53</sup>. Haplotype analysis of the most informative families, eleven in total, was conducted to verify whether the exon 11 deletion of *PALB2* could be a recurrent event arose independently in multiple individuals and resulting in a similar phenotypic effect or be passed down through generations from a common ancestor. The analysis revealed that six families share a chromosomal segment of about eight centimorgans (cM) encompassing the variant, consistent with a relatively recent founder event. One family exhibited a partially common haplotype that may have resulted from a recombination event between *PALB2* and D16S3046. Two families share neither the haplotype associated with

the rearrangement nor the haplotypes identified by Sidoti and collaborators. However, the distance between the microsatellite markers analyzed does not exclude the presence of a smaller shared haplotype among these families and possibly the ones identified in the adjacent region of Tuscany.

Expanding data collection to nearby centers and analyzing microsatellites in closer proximity to the *PALB2* gene may enhance our understanding of distribution of the *PALB2* Exon 11 deletion in Italy and fine-map the haplotype, while international collaborations will be essential to fully elucidate the prevalence and clinical impact of this rare variant. In this context, joining efforts with initiatives such as the PALB2 Interest Group (<https://www.palb2.org/team/palb2-interest-group/>) could provide access to larger datasets and promote coordinated research efforts across populations.

## CONCLUSIONS

The use of NGS-based multigene panels has expanded the number of genes routinely tested in diagnostics and, at the same time, has produced robust data suitable for simultaneous sequence and copy number analyses. In our cohort, the combination of these factors disclosed both expected and unexpected results: as expected, a higher positive predictive value for the test, but also an unforeseen unique contribution of a single CNV suggestive of a founder effect, to the diagnostic yield.

These results emphasize both the broad, global potential of NGS combined sequence and copy number analyses and the importance of understanding and addressing local variations and specificities.

## Data Availability

Data supporting this study's findings are available in the supplement materials. Full patients' data are not available publicly to respect of participant privacy and consent.

Not shown data are available upon request to Dr. Elena Tenedini, [elena.tenedini@unimore.it](mailto:elena.tenedini@unimore.it)

### **Conflict of Interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### **Funding**

This research was funded in parts by the European Union - Next Generation EU, Mission 4 Component 1 CUP E53D23012150001 to Elena Tenedini; Italian Ministry of University and Research "Dipartimento d'eccellenza 2023/2027" CUP E53C23000170001 to Enrico Tagliafico and European Union - NextGenerationEU through the Italian Ministry of University and Research under PRIN PNRR - M4C2-I1.3 Project PE\_00000019 "HEAL ITALIA" to Angela Toss, Rossella Manfredini, Massimo Dominici, CUP E93C22001860006.

### **Acknowledgments**

The authors thank the Angela Serra Association for Cancer Research for support to patients care and research activities and Miriam Fiori and Teresa Rauseo for effective organization, participation, and contribution to the study.

### **Author Contributions**

Conceptualization: L.B., E.Te., E.Ta.; Formal analysis: L.B., E.Te., D.S.; Data curation: L.B., E.Te., L.A., M.M., D.S., C.P., L.P., I.M.; Resources: L.B., E.Te., L.A., M.M.; I.M.; A.T., E.B., M.V., L.C.D.S., C.P.; Writing original draft: L.B., E.Te., E.Ta., L.A., M.M., A.T., L.C., Writing review: E.Te., L.P., E.Ta., R.M., M.D., L.C.; All authors reviewed and approved the manuscript prior to submission.

## Ethics Declaration

Written informed consent was obtained from all of the patients that were educated about the significance and limitations of NGS diagnostics and the potential for incidental findings.

All genetic analyses and investigations were performed in accordance with the guidelines of the Declaration of Helsinki and this study was approved by local ethic committee (Area Vasta Emilia Nord Ethics Committee, number 32/2024/OSS\*/AOUMO SIRER ID 7122).

## Supplemental Material Summary

-Supplementary Figure 1: Distribution of SNVs/Indels. A) Pathogenic/Likely-Pathogenic SNVs or Indels. 416 P/LP variants were detected in 395 patients; variant counts per gene are shown above each bar, with unique variants in parentheses. B) VUS alterations. 1983 VUS SNVs or Indels were identified in 2949 individuals; variant counts per gene are shown.

-Supplementary Figure 2: Geographic origin of *PALB2* exon 11 deletion carriers. The map displays the birthplaces of carriers, marked by red circles. The red dashed line indicates the Modena and Reggio Emilia provincial borders, main areas served by the laboratory. The Po River appears as a blue line above; the Apennine Mountains range below. Source: Google Maps, edited by the author. Accessed on September 2, 2024.

-Supplementary Table 1: Personal and family clinical details of the study population

-Supplementary Table 2: Comparison of variants analysis results in our study population and recently published studies.

-Supplementary Table 3: CNVs full list

- Supplementary Table 4: *PALB2* pathogenic variant full list

- Supplementary Table 5: Details of *PALB2* exon 11 CNVs reported in the literature

## REFERENCES

1. Couch FJ, Nathanson KL, Offit K. Two Decades After *BRCA*: Setting Paradigms in Personalized Cancer Care and Prevention. *Science*. 2014;343:1466–70. <https://doi.org/10.1126/science.1251827>
2. Melchor L, Benítez J. The complex genetic landscape of familial breast cancer. *Hum Genet*. 2013;132:845–63. <https://doi.org/10.1007/s00439-013-1299-y>
3. Shah PD, Nathanson KL. Application of Panel-Based Tests for Inherited Risk of Cancer. *Annu Rev Genomics Hum Genet*. 2017;18:201–27. <https://doi.org/10.1146/annurev-genom-091416-035305>
4. Susswein LR, Marshall ML, Nusbaum R, Vogel Postula KJ, Weissman SM, Yackowski L, Vaccari EM, Bissonnette J, Booker JK, Cremona ML, Gibellini F, Murphy PD, Pineda-Alvarez DE, Pollevick GD, Xu Z, Richard G, Bale S, Klein RT, Hruska KS, Chung WK. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. *Genet Med*. 2016;18:823–32. <https://doi.org/10.1038/gim.2015.166>
5. Lee K, Seifert BA, Shimelis H, Ghosh R, Crowley SB, Carter NJ, Doonanco K, Foreman AK, Ritter DI, Jimenez S, Trapp M, Offit K, Plon SE, Couch FJ. Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. *Genet Med*. 2019;21:1497–506. <https://doi.org/10.1038/s41436-018-0361-5>
6. Bhai P, Levy MA, Rooney K, Carere DA, Reilly J, Kerkhof J, Volodarsky M, Stuart A, Kadour M, Panabaker K, Schenkel LC, Lin H, Ainsworth P, Sadikovic B. Analysis of Sequence and Copy Number Variants in Canadian Patient Cohort With Familial Cancer Syndromes Using

a Unique Next Generation Sequencing Based Approach. *Front Genet.* 2021;12.

<https://doi.org/10.3389/fgene.2021.698595>

7. LaDuca H, Polley EC, Yussuf A, Hoang L, Gutierrez S, Hart SN, Yadav S, Hu C, Na J, Goldgar DE, Fulk K, Smith LP, Horton C, Profato J, Pesaran T, Gau C-L, Pronold M, Davis BT, Chao EC, Couch FJ, Dolinsky JS. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. *Genet Med.* 2020;22:407–15.  
<https://doi.org/10.1038/s41436-019-0633-8>

8. Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, Pooley KA, Parsons MT, Fortuno C, Wang Q, Bolla MK, Dennis J, Keeman R, Alonso MR, Álvarez N, Herraes B, Fernandez V, Núñez-Torres R, Osorio A, Valcich J, Li M, Törngren T, Harrington PA, Baynes C, Conroy DM, Decker B, Fachal L, Mavaddat N, Ahearn T, Aittomäki K, Antonenkova NN, Arnold N, Arveux P, Ausems MGEM, Auvinen P, Becher H, Beckmann MW, Behrens S, Bermisheva M, Białkowska K, Blomqvist C, Bogdanova NV, Bogdanova-Markov N, Bojesen SE, Bonanni B, Børresen-Dale A-L, Brauch H, Bremer M, Briceno I, Brüning T, Burwinkel B, Cameron DA, Camp NJ, Campbell A, Carracedo A, Castelao JE, Cessna MH, Chanock SJ, Christiansen H, Collée JM, Cordina-Duverger E, Cornelissen S, Czene K, Dörk T, Ekici AB, Engel C, Eriksson M, Fasching PA, Figueroa J, Flyger H, Försti A, Gabrielson M, Gago-Dominguez M, Georgoulas V, Gil F, Giles GG, Glendon G, Garcia EBG, Alnæs GIG, Guénel P, Hadjisavvas A, Haeberle L, Hahnen E, Hall P, Hamann U, Harkness EF, Hartikainen JM, Hartman M, He W, Heemskerk-Gerritsen BAM, Hillemanns P, Hogervorst FBL, Hollestelle A, Ho WK, Hooning MJ, Howell A, Humphreys K, Idris F, Jakubowska A, Jung A, Kapoor PM, Kerin MJ, Khusnutdinova E, Kim S-W, Ko Y-D, Kosma V-M, Kristensen VN, Kyriacou K, Lakeman IMM, Lee JW, Lee MH, Li J, Lindblom A, Lo W-Y, Loizidou MA, Lophatananon A,

- 477 Lubiński J, MacInnis RJ, Madsen MJ, Mannermaa A, Manoochehri M, Manoukian S,  
 478 Margolin S, Martinez ME, Maurer T, Mavroudis D, McLean C, Meindl A, Mensenkamp AR,  
 479 Michailidou K, Miller N, Mohd Taib NA, Muir K, Mulligan AM, Nevanlinna H, Newman WG,  
 480 Nordestgaard BG, Ng P-S, Oosterwijk JC, Park SK, Park-Simon T-W, Perez JIA, Peterlongo  
 481 P, Porteous DJ, Prajzandanc K, Prokofyeva D, Radice P, Rashid MU, Rhenius V, Rookus  
 482 MA, Rüdiger T, Saloustros E, Sawyer EJ, Schmutzler RK, Schneeweiss A, Schürmann P,  
 483 Shah M, Sohn C, Southey MC, Surowy H, Suvanto M, Thanasihtichai S, Tomlinson I,  
 484 Torres D, Truong T, Tzardi M, Valova Y, van Asperen CJ, Van Dam RM, van den Ouweland  
 485 AMW, van der Kolk LE, van Veen EM, Wendt C, Williams JA, Yang XR, Yoon S-Y, Zamora  
 486 MP, Evans DG, de la Hoya M, Simard J, Antoniou AC, Borg Å, Andrulis IL, Chang-Claude J,  
 487 García-Closas M, Chenevix-Trench G, Milne RL, Pharoah PDP, Schmidt MK, Spurdle AB,  
 488 Vreeswijk MPG, Benitez J, Dunning AM, Kvist A, Teo SH, Devilee P, Easton DF. Breast  
 489 Cancer Risk Genes - Association Analysis in More than 113,000 Women. *N Engl J Med*.  
 490 2021;384:428–39. <https://doi.org/10.1056/NEJMoa1913948>
- 491 9. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial  
 492 High-Risk Assessment: Breast, Ovarian, and Pancreatic Guideline Version 3.2024 ©  
 493 National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed [05/25,  
 494 2024]
- 495 10. Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM,  
 496 Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M,  
 497 Ledermann JA, Loibl S, Phillips K-A, Paluch-Shimon S. Risk reduction and screening of  
 498 cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.  
 499 *Ann Oncol*. 2023;34:33–47. <https://doi.org/10.1016/j.annonc.2022.10.004>

- 500 11. Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S,  
501 Goggins M, Hutton ML, CGC, Karlan BY, Khan S, Klein C, Kohlmann W, CGC, Kurian AW,  
502 Laronga C, Litton JK, Mak JS, LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K,  
503 Pederson HJ, Reiser G, CGC, Senter-Jamieson L, CGC, Shannon KM, Shatsky R,  
504 Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA.  
505 Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021,  
506 NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2021;19:77–102.  
507 <https://doi.org/10.6004/jnccn.2021.0001>
- 508 12. Mancini-DiNardo D, Judkins T, Kidd J, Bernhisel R, Daniels C, Brown K, Meek K, Craft J,  
509 Holladay J, Morris B, Roa BB. Detection of large rearrangements in a hereditary pan-cancer  
510 panel using next-generation sequencing. *BMC Med Genomics*. 2019;12:138.  
511 <https://doi.org/10.1186/s12920-019-0587-3>
- 512 13. Henkel J, Laner A, Locher M, Wohlfrom T, Neitzel B, Becker K, Neuhaus T, Abicht A,  
513 Steinke-Lange V, Holinski-Feder E. Diagnostic yield and clinical relevance of expanded  
514 germline genetic testing for nearly 7000 suspected HBOC patients. *Eur J Hum Genet*.  
515 2023;31:925–30. <https://doi.org/10.1038/s41431-023-01380-2>
- 516 14. Bozsik A, Pócza T, Papp J, Vaszkó T, Butz H, Patócs A, Oláh E. Complex Characterization  
517 of Germline Large Genomic Rearrangements of the BRCA1 and BRCA2 Genes in High-  
518 Risk Breast Cancer Patients—Novel Variants from a Large National Center. *Int J Mol Sci*.  
519 2020;21:4650. <https://doi.org/10.3390/ijms21134650>
- 520 15. Pócza T, Grolmusz VK, Papp J, Butz H, Patócs A, Bozsik A. Germline Structural Variations  
521 in Cancer Predisposition Genes. *Front Genet*. 2021;12.  
522 <https://doi.org/10.3389/fgene.2021.634217>

16. Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, Raca G, Ritter DI, South ST, Thorland EC, Pineda-Alvarez D, Aradhya S, Martin CL. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). *Genet Med Off J Am Coll Med Genet*. 2020;22:245–57. <https://doi.org/10.1038/s41436-019-0686-8>
17. Lepkes L, Kayali M, Blümcke B, Weber J, Suszynska M, Schmidt S, Borde J, Klonowska K, Wappenschmidt B, Hauke J, Kozlowski P, Schmutzler RK, Hahnen E, Ernst C. Performance of In Silico Prediction Tools for the Detection of Germline Copy Number Variations in Cancer Predisposition Genes in 4208 Female Index Patients with Familial Breast and Ovarian Cancer. *Cancers*. 2021;13:118. <https://doi.org/10.3390/cancers13010118>
18. Singh AK, Olsen MF, Lavik LAS, Vold T, Drabløs F, Sjørusen W. Detecting copy number variation in next generation sequencing data from diagnostic gene panels. *BMC Med Genomics*. 2021;14. <https://doi.org/10.1186/s12920-021-01059-x>
19. Tsaousis GN, Papadopoulou E, Apeossos A, Agiannitopoulos K, Pepe G, Kampouri S, Diamantopoulos N, Floros T, Iosifidou R, Katopodi O, Koumarianou A, Markopoulos C, Papazisis K, Venizelos V, Xanthakis I, Xepapadakis G, Banu E, Eniu DT, Negru S, Stanculeanu DL, Ungureanu A, Ozmen V, Tansan S, Tekinel M, Yalcin S, Nasioulas G. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations. *BMC Cancer*. 2019;19:535. <https://doi.org/10.1186/s12885-019-5756-4>
20. Agiannitopoulos K. Copy Number Variations (CNVs) Account for 10.8% of Pathogenic Variants in Patients Referred for Hereditary Cancer Testing. *Cancer Genomics Proteomics*. 2023. <https://doi.org/10.21873/cgp.20396>

- 547 21. Gordeeva V, Sharova E, Arapidi G. Progress in Methods for Copy Number Variation  
548 Profiling. *Int J Mol Sci.* 2022;23:2143. <https://doi.org/10.3390/ijms23042143>
- 549 22. Moreno-Cabrera JM, Del Valle J, Feliubadaló L, Pineda M, González S, Campos O, Cuesta  
550 R, Brunet J, Serra E, Capellà G, Gel B, Lázaro C. Screening of CNVs using NGS data  
551 improves mutation detection yield and decreases costs in genetic testing for hereditary  
552 cancer. *J Med Genet.* 2022;59:75–8. <https://doi.org/10.1136/jmedgenet-2020-107366>
- 553 23. Raca G, Astbury C, Behlmann A, De Castro MJ, Hickey SE, Karaca E, Lowther C, Riggs  
554 ER, Seifert BA, Thorland EC, Deignan JL, ACMG Laboratory Quality Assurance Committee.  
555 Electronic address: documents@acmg.net. Points to consider in the detection of germline  
556 structural variants using next-generation sequencing: A statement of the American College  
557 of Medical Genetics and Genomics (ACMG). *Genet Med Off J Am Coll Med Genet.*  
558 2023;25:100316. <https://doi.org/10.1016/j.gim.2022.09.017>
- 559 24. Lerner-Ellis J, Mighton C, Lazaro C, Watkins N, Di Gioacchino V, Wong A, Chang MC,  
560 Charames GS. Multigene panel testing for hereditary breast and ovarian cancer in the  
561 province of Ontario. *J Cancer Res Clin Oncol.* 2021;147:871–9.  
562 <https://doi.org/10.1007/s00432-020-03377-6>
- 563 25. Öfverholm A, Törngren T, Rosén A, Arver B, Einbeigi Z, Haraldsson K, Ståhlbom AK,  
564 Kuchinskaya E, Lindblom A, Melin B, Paulsson-Karlsson Y, Stenmark-Askmal M, Tham E,  
565 Von Wachenfeldt A, Kvist A, Borg Å, Ehrencrona H. Extended genetic analysis and tumor  
566 characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.  
567 *BMC Cancer.* 2023;23:738. <https://doi.org/10.1186/s12885-023-11229-y>
- 568 26. Toss A, Piombino C, Tenedini E, Bologna A, Gasparini E, Tarantino V, Filieri ME, Cottafavi  
569 L, Giovanardi F, Madrigali S, Civallero M, Marcheselli L, Marchi I, Domati F, Venturelli M,

Barbieri E, Grandi G, Tagliafico E, Cortesi L. The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study. *Diagn Basel Switz*. 2021;11:565. <https://doi.org/10.3390/diagnostics11030565>

27. Toss A, Tenedini E, Piombino C, Venturelli M, Marchi I, Gasparini E, Barbieri E, Razzaboni E, Domati F, Caggia F, Grandi G, Combi F, Tazzioli G, Dominici M, Tagliafico E, Cortesi L. Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers. *Genes*. 2021;12:616. <https://doi.org/10.3390/genes12050616>

28. Tenedini E, Celestini F, Iapicca P, Marino M, Castellano S, Artuso L, Biagiarelli F, Cortesi L, Toss A, Barbieri E, Roncucci L, Pedroni M, Manfredini R, Luppi M, Trenti T, Tagliafico E. Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework. *Diagn Berl Ger*. 2021;9:115–22. <https://doi.org/10.1515/dx-2021-0051>

29. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, Maglott DR. ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic Acids Res*. 2014;42:D980–5. <https://doi.org/10.1093/nar/gkt1113>

30. Fokkema IFAC, Taschner PEM, Schaafsma GCP, Celli J, Laros JFJ, den Dunnen JT. LOVD v.2.0: the next generation in gene variant databases. *Hum Mutat*. 2011;32:557–63. <https://doi.org/10.1002/humu.21438>

31. Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, Massouras A. VarSome: the human genomic variant search engine. *Bioinformatics*. 2019;35:1978–80. <https://doi.org/10.1093/bioinformatics/bty897>

32. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res*. 2010;38:e164. <https://doi.org/10.1093/nar/gkq603>

- 593 33. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the  
594 consequences of genomic variants with the Ensembl API and SNP Effect Predictor.  
595 *Bioinformatics*. 2010;26:2069–70. <https://doi.org/10.1093/bioinformatics/btq330>
- 596 34. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E,  
597 Spector E, Voelkerding K, Rehm HL. Standards and guidelines for the interpretation of  
598 sequence variants: a joint consensus recommendation of the American College of Medical  
599 Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*.  
600 2015;17:405–24. <https://doi.org/10.1038/gim.2015.30>
- 601 35. Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, Ledbetter DH,  
602 Maglott DR, Martin CL, Nussbaum RL, Plon SE, Ramos EM, Sherry ST, Watson MS.  
603 ClinGen — The Clinical Genome Resource. *N Engl J Med*. 2015;372:2235–42.  
604 <https://doi.org/10.1056/NEJMSr140626>
- 605 36. Bouras A, Lafaye C, Leone M, Kherraf Z-E, Martin-Denavit T, Fert-Ferrer S, Calender A,  
606 Boutry-Kryza N. Identification and Characterization of an Exonic Duplication in PALB2 in a  
607 Man with Synchronous Breast and Prostate Cancer. *Int J Mol Sci*. 2022;23:667.  
608 <https://doi.org/10.3390/ijms23020667>
- 609 37. Schrader KA, Stratton KL, Murali R, Laitman Y, Cavallone L, Offit L, Wen YH, Thomas T,  
610 Shah S, Rau-Murthy R, Manschreck C, Salo-Mullen E, Otegbeye E, Corines M, Zhang L,  
611 Norton L, Hudis C, Klein RJ, Kauff ND, Robson M, Stadler ZK, Haber DA, Lipkin SM,  
612 Friedman E, Foulkes WD, Altshuler D, Vijai J, Offit K. Genome Sequencing of Multiple  
613 Primary Tumors Reveals a Novel PALB2 Variant. *J Clin Oncol Off J Am Soc Clin Oncol*.  
614 2016;34:e61-67. <https://doi.org/10.1200/JCO.2013.50.0272>

38. Sidoti D, Margotta V, Calosci D, Fiorentini E, Bacci C, Gensini F, Papi L, Montini M. Alu-Mediated Duplication and Deletion of Exon 11 Are Frequent Mechanisms of PALB2 Inactivation, Predisposing Individuals to Hereditary Breast–Ovarian Cancer Syndrome. *Cancers*. 2024;16:4022. <https://doi.org/10.3390/cancers16234022>
39. Kurian AW, Ward KC, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Morrow M, Berek JS, Hofer TP, Katz SJ. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. *J Clin Oncol Off J Am Soc Clin Oncol*. 2021;39:1631–40. <https://doi.org/10.1200/JCO.20.02785>
40. Horton C, Hoang L, Zimmermann H, Young C, Grzybowski J, Durda K, Vuong H, Burks D, Cass A, LaDuca H, Richardson ME, Harrison S, Chao EC, Karam R. Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing. *JAMA Oncol*. 2024;10:212. <https://doi.org/10.1001/jamaoncol.2023.5586>
41. Ducey M, Sesma-Sanz L, Guitton-Sert L, Lashgari A, Gao Y, Brahiti N, Rodrigue A, Margaillan G, Caron M-C, Côté J, Simard J, Masson J-Y. The Tumor Suppressor PALB2: Inside Out. *Trends Biochem Sci*. 2019;44:226–40. <https://doi.org/10.1016/j.tibs.2018.10.008>
42. Zhang F, Fan Q, Ren K, Andreassen PR. PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2. *Mol Cancer Res*. 2009;7:1110–8. <https://doi.org/10.1158/1541-7786.MCR-09-0123>
43. Tischkowitz M, Balmaña J, Foulkes WD, James P, Ngeow J, Schmutzler R, Voian N, Wick MJ, Stewart DR, Pal T, ACMG Professional Practice and Guidelines Committee. Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med Off J Am Coll Med Genet*. 2021;23:1416–23. <https://doi.org/10.1038/s41436-021-01151-8>

- 638 44. Zhou J, Wang H, Fu F, Li Z, Feng Q, Wu W, Liu Y, Wang C, Chen Y. Spectrum of *PALB2*  
639 germline mutations and characteristics of *PALB2* -related breast cancer: Screening of  
640 16,501 unselected patients with breast cancer and 5890 controls by next-generation  
641 sequencing. *Cancer*. 2020;126:3202–8. <https://doi.org/10.1002/cncr.32905>
- 642 45. Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, Gao C, Lilyquist J, Yadav S,  
643 Boddicker NJ, Samara R, Klebba J, Ambrosone CB, Anton-Culver H, Auer P, Bandera EV,  
644 Bernstein L, Bertrand KA, Burnside ES, Carter BD, Eliassen H, Gapstur SM, Gaudet M,  
645 Haiman C, Hodge JM, Hunter DJ, Jacobs EJ, John EM, Kooperberg C, Kurian AW, Le  
646 Marchand L, Lindstroem S, Lindstrom T, Ma H, Neuhausen S, Newcomb PA, O'Brien KM,  
647 Olson JE, Ong IM, Pal T, Palmer JR, Patel AV, Reid S, Rosenberg L, Sandler DP, Scott C,  
648 Tamimi R, Taylor JA, Trentham-Dietz A, Vachon CM, Weinberg C, Yao S, Ziogas A, Weitzel  
649 JN, Goldgar DE, Domchek SM, Nathanson KL, Kraft P, Polley EC, Couch FJ. A Population-  
650 Based Study of Genes Previously Implicated in Breast Cancer. *N Engl J Med*.  
651 2021;384:440–51. <https://doi.org/10.1056/NEJMoa2005936>
- 652 46. Yadav S, Boddicker NJ, Na J, Polley EC, Hu C, Hart SN, Gnanaolivu RD, Larson N,  
653 Holtegaard S, Huang H, Dunn CA, Teras LR, Patel AV, Lacey JV, Neuhausen SL, Martinez  
654 E, Haiman C, Chen F, Ruddy KJ, Olson JE, John EM, Kurian AW, Sandler DP, O'Brien KM,  
655 Taylor JA, Weinberg CR, Anton-Culver H, Ziogas A, Zirpoli G, Goldgar DE, Palmer JR,  
656 Domchek SM, Weitzel JN, Nathanson KL, Kraft P, Couch FJ. Contralateral Breast Cancer  
657 Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2,  
658 and PALB2. *J Clin Oncol Off J Am Soc Clin Oncol*. 2023;41:1703–13.  
659 <https://doi.org/10.1200/JCO.22.01239>
- 660 47. Breast Cancer Association Consortium, Mavaddat N, Dorling L, Carvalho S, Allen J,  
661 González-Neira A, Keeman R, Bolla MK, Dennis J, Wang Q, Ahearn TU, Andrulis IL,

Beckmann MW, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV,  
 Bojesen SE, Briceno I, Brüning T, Camp NJ, Campbell A, Castelao JE, Chang-Claude J,  
 Chanock SJ, Chenevix-Trench G, Christiansen H, Czene K, Dörk T, Eriksson M, Evans DG,  
 Fasching PA, Figueroa JD, Flyger H, Gabrielson M, Gago-Dominguez M, Geisler J, Giles  
 GG, Guénel P, Hadjisavvas A, Hahnen E, Hall P, Hamann U, Hartikainen JM, Hartman M,  
 Hoppe R, Howell A, Jakubowska A, Jung A, Khusnutdinova EK, Kristensen VN, Li J, Lim  
 SH, Lindblom A, Loizidou MA, Lophatananon A, Lubinski J, Madsen MJ, Mannermaa A,  
 Manoochchri M, Margolin S, Mavroudis D, Milne RL, Mohd Taib NA, Morra A, Muir K, Obi N,  
 Osorio A, Park-Simon T-W, Peterlongo P, Radice P, Saloustros E, Sawyer EJ, Schmutzler  
 RK, Shah M, Sim X, Southey MC, Thorne H, Tomlinson I, Torres D, Truong T, Yip CH,  
 Spurdle AB, Vreeswijk MPG, Dunning AM, García-Closas M, Pharoah PDP, Kvist A,  
 Muranen TA, Nevanlinna H, Teo SH, Devilee P, Schmidt MK, Easton DF. Pathology of  
 Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility  
 Genes. *JAMA Oncol.* 2022;8:e216744. <https://doi.org/10.1001/jamaoncol.2021.6744>

48. Yang X, Leslie G, Doroszk A, Schneider S, Allen J, Decker B, Dunning AM, Redman J,  
 Scarth J, Plaskocinska I, Luccarini C, Shah M, Pooley K, Dorling L, Lee A, Adank MA,  
 Adlard J, Aittomäki K, Andrulis IL, Ang P, Barwell J, Bernstein JL, Bobolis K, Borg Å,  
 Blomqvist C, Claes KBM, Concannon P, Cuggia A, Culver JO, Damiola F, De Pauw A, Diez  
 O, Dolinsky JS, Domchek SM, Engel C, Evans DG, Fostira F, Garber J, Golmard L, Goode  
 EL, Gruber SB, Hahnen E, Hake C, Heikkinen T, Hurley JE, Janavicius R, Kleibl Z,  
 Kleiblova P, Konstantopoulou I, Kvist A, Laduca H, Lee ASG, Lesueur F, Maher ER,  
 Mannermaa A, Manoukian S, McFarland R, McKinnon W, Meindl A, Metcalfe K, Mohd Taib  
 NA, Moilanen J, Nathanson KL, Neuhausen S, Ng PS, Nguyen-Dumont T, Nielsen SM,  
 Obermair F, Offit K, Olopade OI, Ottini L, Penkert J, Pylkäs K, Radice P, Ramus SJ,  
 Rudaitis V, Side L, Silva-Smith R, Silvestri V, Skytte A-B, Slavin T, Soukupova J, Tondini C,

687 Trainer AH, Unzeitig G, Usha L, Van Overeem Hansen T, Whitworth J, Wood M, Yip CH,  
 688 Yoon S-Y, Yussuf A, Zogopoulos G, Goldgar D, Hopper JL, Chenevix-Trench G, Pharoah P,  
 689 George SHL, Balmaña J, Houdayer C, James P, El-Haffaf Z, Ehrencrona H, Janatova M,  
 690 Peterlongo P, Nevanlinna H, Schmutzler R, Teo S-H, Robson M, Pal T, Couch F, Weitzel  
 691 JN, Elliott A, Southey M, Winqvist R, Easton DF, Foulkes WD, Antoniou AC, Tischkowitz M.  
 692 Cancer Risks Associated With Germline *PALB2* Pathogenic Variants: An International Study  
 693 of 524 Families. *J Clin Oncol*. 2020;38:674–85. <https://doi.org/10.1200/JCO.19.01907>

694 49. Song H, Dicks EM, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell DD, Traficante N,  
 695 Group A, Brenton J, Goranova T, Hosking K, Piskorz A, van Oudenhove E, Doherty J,  
 696 Harris HR, Rossing MA, Duerst M, Dork T, Bogdanova NV, Modugno F, Moysich K, Odunsi  
 697 K, Ness R, Karlan BY, Lester J, Jensen A, Krüger Kjaer S, Høgdall E, Campbell IG, Lázaro  
 698 C, Pujara MA, Cunningham J, Vierkant R, Winham SJ, Hildebrandt M, Huff C, Li D, Wu X,  
 699 Yu Y, Permuth JB, Levine DA, Schildkraut JM, Riggan MJ, Berchuck A, Webb PM, Group  
 700 OS, Cybulski C, Gronwald J, Jakubowska A, Lubinski J, Alsop J, Harrington P, Chan I,  
 701 Menon U, Pearce CL, Wu AH, de Fazio A, Kennedy CJ, Goode E, Ramus S, Gayther S,  
 702 Pharoah P. Population-based targeted sequencing of 54 candidate genes identifies *PALB2*  
 703 as a susceptibility gene for high-grade serous ovarian cancer. *J Med Genet*. 2021;58:305–  
 704 13. <https://doi.org/10.1136/jmedgenet-2019-106739>

705 50. Toss A, Ponzoni O, Riccò B, Piombino C, Moscetti L, Combi F, Palma E, Papi S, Tenedini  
 706 E, Tazzioli G, Dominici M, Cortesi L. Management of *PALB2*-associated breast cancer: A  
 707 literature review and case report. *Clin Case Rep*. 2023;11:e7747.  
 708 <https://doi.org/10.1002/ccr3.7747>

- 709 51. Cilento MA, Poplawski NK, Paramasivam S, Thomas DM, Kichenadasse G. Germline  
710 PALB2 Variants and PARP Inhibitors in Endometrial Cancer. *J Natl Compr Cancer Netw*  
711 *JNCCN*. 2021;19:1212–7. <https://doi.org/10.6004/jnccn.2021.7067>
- 712 52. Park JS, Shin S, Lee YJ, Lee S-T, Nam EJ, Han JW, Lee SH, Kim TI, Park HS. Implication  
713 and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with  
714 BRCA1/2 Mutation-Negative Breast Cancer. *Cancer Res Treat*. 2022;54:1099–110.  
715 <https://doi.org/10.4143/crt.2021.978>
- 716 53. Sen SK, Han K, Wang J, Lee J, Wang H, Callinan PA, Dyer M, Cordaux R, Liang P, Batzer  
717 MA. Human genomic deletions mediated by recombination between Alu elements. *Am J*  
718 *Hum Genet*. 2006;79:41–53. <https://doi.org/10.1086/504600>